Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
INO's Cash to Debt is ranked higher than
85% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. INO: No Debt )
INO' s 10-Year Cash to Debt Range
Min: 0.97   Max: No Debt
Current: No Debt

Equity to Asset 0.86
INO's Equity to Asset is ranked higher than
89% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. INO: 0.86 )
INO' s 10-Year Equity to Asset Range
Min: 0.44   Max: 0.95
Current: 0.86

0.44
0.95
Interest Coverage No Debt
INO's Interest Coverage is ranked higher than
74% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INO: No Debt )
INO' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 15.58
M-Score: 0.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -157.54
INO's Operating margin (%) is ranked higher than
66% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. INO: -157.54 )
INO' s 10-Year Operating margin (%) Range
Min: -8188.89   Max: -82.67
Current: -157.54

-8188.89
-82.67
Net-margin (%) -390.31
INO's Net-margin (%) is ranked higher than
60% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. INO: -390.31 )
INO' s 10-Year Net-margin (%) Range
Min: -5759.26   Max: -79.32
Current: -390.31

-5759.26
-79.32
ROE (%) -86.12
INO's ROE (%) is ranked higher than
62% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. INO: -86.12 )
INO' s 10-Year ROE (%) Range
Min: -152.12   Max: -32.52
Current: -86.12

-152.12
-32.52
ROA (%) -65.11
INO's ROA (%) is ranked higher than
60% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. INO: -65.11 )
INO' s 10-Year ROA (%) Range
Min: -98.97   Max: -25.77
Current: -65.11

-98.97
-25.77
ROC (Joel Greenblatt) (%) -1045.78
INO's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. INO: -1045.78 )
INO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7552.88   Max: -481.97
Current: -1045.78

-7552.88
-481.97
Revenue Growth (%) 6.50
INO's Revenue Growth (%) is ranked higher than
81% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. INO: 6.50 )
INO' s 10-Year Revenue Growth (%) Range
Min: -78   Max: 180.2
Current: 6.5

-78
180.2
EBITDA Growth (%) -16.80
INO's EBITDA Growth (%) is ranked higher than
67% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. INO: -16.80 )
INO' s 10-Year EBITDA Growth (%) Range
Min: -28.1   Max: 15.7
Current: -16.8

-28.1
15.7
EPS Growth (%) 28.10
INO's EPS Growth (%) is ranked higher than
93% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. INO: 28.10 )
INO' s 10-Year EPS Growth (%) Range
Min: -40.3   Max: 57.1
Current: 28.1

-40.3
57.1
» INO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

INO Guru Trades in Q3 2013

Louis Moore Bacon 100,000 sh (New)
» More
Q4 2013

INO Guru Trades in Q4 2013

Jean-Marie Eveillard 250,000 sh (New)
Louis Moore Bacon Sold Out
» More
Q1 2014

INO Guru Trades in Q1 2014

Paul Tudor Jones 31,085 sh (New)
Jean-Marie Eveillard Sold Out
» More
Q2 2014

INO Guru Trades in Q2 2014

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-03-31 Sold Out $9.76 - $15.28 $ 10-16%0
Jean-Marie Eveillard 2013-12-31 New Buy$6.92 - $11.88 $ 1021%250000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Inovio Pharmaceuticals Inc

Inovio CEO Invests in 250,000 Shares of Company Stock
The CEO of Inovio Pharmaceuticals Inc (INO), Jong Joseph Kim, purchased 250,000 shares for $2,265,000 on August 12. The average price per share was $9.06. Read more...

Ratios

vs
industry
vs
history
P/B 4.95
INO's P/B is ranked higher than
76% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. INO: 4.95 )
INO' s 10-Year P/B Range
Min: 0.38   Max: 13.16
Current: 4.95

0.38
13.16
P/S 30.30
INO's P/S is ranked higher than
69% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. INO: 30.30 )
INO' s 10-Year P/S Range
Min: 1.57   Max: 1464
Current: 30.3

1.57
1464
EV-to-EBIT -17.73
INO's EV-to-EBIT is ranked higher than
76% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INO: -17.73 )
INO' s 10-Year EV-to-EBIT Range
Min: 349.7   Max: 5578.8
Current: -17.73

349.7
5578.8
Current Ratio 9.73
INO's Current Ratio is ranked higher than
89% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. INO: 9.73 )
INO' s 10-Year Current Ratio Range
Min: 0.82   Max: 16.04
Current: 9.73

0.82
16.04
Quick Ratio 9.73
INO's Quick Ratio is ranked higher than
89% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. INO: 9.73 )
INO' s 10-Year Quick Ratio Range
Min: 0.82   Max: 16.04
Current: 9.73

0.82
16.04

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.80
INO's Price/Net Cash is ranked higher than
89% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 190.00 vs. INO: 6.80 )
INO' s 10-Year Price/Net Cash Range
Min: 2.25   Max: 288
Current: 6.8

2.25
288
Price/Net Current Asset Value 6.66
INO's Price/Net Current Asset Value is ranked higher than
88% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. INO: 6.66 )
INO' s 10-Year Price/Net Current Asset Value Range
Min: 2.15   Max: 288
Current: 6.66

2.15
288
Price/Tangible Book 5.65
INO's Price/Tangible Book is ranked higher than
80% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. INO: 5.65 )
INO' s 10-Year Price/Tangible Book Range
Min: 1.14   Max: 20.53
Current: 5.65

1.14
20.53
Price/Median PS Value 1.77
INO's Price/Median PS Value is ranked higher than
73% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. INO: 1.77 )
INO' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 58.82
Current: 1.77

0.24
58.82
Forward Rate of Return (Yacktman) -15.25
INO's Forward Rate of Return (Yacktman) is ranked higher than
71% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. INO: -15.25 )
INO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -13.2   Max: -6.5
Current: -15.25

-13.2
-6.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:GBMB.Germany
Inovio Biomedical Corporation was originally incorporated on June 29, 1983, under the laws of California as Biotechnologies & Experimental Research, Inc. The entity changed its corporate name to BTX, Inc. on December 10, 1991, and Genetronics, Inc. on February 8, 1994. On April 14, 1994, the board of directors approved a share exchange agreement with Consolidated United Safety Technologies Inc. On September 2, 1997, it listed on the Toronto Stock Exchange as Genetronics Biomedical Ltd, under the laws of British Columbia, Canada, which wholly owned Genetronics, Inc. On June 15, 2001, it completed a change in jurisdiction of incorporation from British Columbia, Canada, to the state of Delaware and became Genetronics Biomedical Corporation, a Delaware corporation. On January 17, 2003, Genetronics voluntarily de-listed from the Toronto Stock Exchange. On March 31, 2005, its corporate name changed from Genetronics Biomedical Corporation to Inovio Biomedical Corporation. On June 1, 2009, it completed the acquisition of VGX Pharmaceuticals, Inc. ('VGX'), a privately-held company, pursuant to the terms of an Amended and Restated Agreement and Plan of Merger dated December 5, 2008, as further amended on March 31, 2009 by and among Inovio, Inovio's wholly-owned subsidiary Inovio Acquisition, LLC and VGX (the 'Merger'). Upon the closing of the Merger, Inovio Acquisition, LLC assumed all of VGX's business, properties and assets and assumed its obligations, changed its name to VGX Pharmaceuticals, LLC, and remains a wholly-owned subsidiary of the Company, utilizing a single, integrated management team with Inovio. On May 14, 2010, the entity changed its corporate name to Inovio Pharmaceuticals, Inc. The company is engaged in the development of a new generation of vaccines and immune therapies, called synthetic vaccines, focused on cancers and infectious diseases. Its DNA-based SynCon technology is designed to provide universal protection against known as well as new unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with its proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Its preclinical development and clinical programs include cervical dysplasia/cancer (therapeutic), influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. The Company faces competition from several development-stage and established enterprises, including major pharmaceutical and biotechnology firms, which are actively engaged in infectious disease and cancer vaccine research and development. Any pharmaceutical products that the Company develops will require regulatory clearances prior to clinical trials and additional regulatory approvals prior to commercialization. As of March 8, 2013, the Company's patent portfolio included over 68 issued United States pate
» More Articles for INO

Headlines

Articles On GuruFocus.com
Inovio CEO Invests in 250,000 Shares of Company Stock Aug 13 2014 
comment on INO May 10 2013 
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
Weekly CFO Buys Highlight: ZBB, INO, LPR, PMC, FGP, PRMW Jun 17 2012 
Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO Jun 11 2012 
Any opinions regarding Apr 12 2010 

More From Our Partners
Sino-Global Shipping America (SINO) Is Weak On High Volume Today Sep 17 2014 - THESTREET

More From Other Websites
INOVIO PHARMACEUTICALS, INC. Financials Sep 18 2014
[$$] Who Is Working on Ebola? Sep 18 2014
Inovio to Present at Upcoming Investor Conferences Sep 18 2014
Inovio Pharmaceuticals (INO) Begins Trading on NASDAQ Global Select Market Exchange Sep 15 2014
INOVIO PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Sep 04 2014
Inovio Pharmaceuticals to List on NASDAQ Sep 04 2014
Inovio to Present at Upcoming Investor Conferences Sep 03 2014
Inovio CEO Invests in 250,000 Shares of Company Stock Aug 13 2014
Inovio Pharmaceuticals (INO) Marked As A Dead Cat Bounce Stock Aug 12 2014
Why Inovio Pharmaceuticals (INO) Stock Is Declining Today Aug 11 2014
Inovio Pharmaceuticals Reports 2014 Second Quarter Financial Results Aug 11 2014
Q2 2014 Inovio Pharmaceuticals Inc Earnings Release - 09:00 am ET Aug 11 2014
INOVIO PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Aug 11 2014
Inovio Pharmaceuticals to Host Second Quarter 2014 Earnings Webcast Live on Monday, August 11, 2014 Aug 08 2014
INOVIO PHARMACEUTICALS, INC. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an... Aug 06 2014
Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 Aug 01 2014
Inovio Data Not A Home Run, But Got Company In Great Scoring Position Jul 25 2014
Inovio Pharma upgraded by Aegis Capital Jul 24 2014
Inovio upgraded to Buy from Hold at Aegis Jul 24 2014
Perilous Reversal Stock: Inovio Pharmaceuticals (INO) Jul 24 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK